SARS-CoV-2 Antibodies in Hemodialysis Patients Six Months after Infection Compared to Healthcare Workers.
Journal
International journal of nephrology
ISSN: 2090-214X
Titre abrégé: Int J Nephrol
Pays: United States
ID NLM: 101546753
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
10
2021
accepted:
16
11
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
The humoral response to SARS-CoV-2 infection in hemodialysis patients needs to be clarified. In this retrospective study performed in two dialysis facilities, we measured the circulating levels of SARS-CoV-2 antibodies in patients who were on maintenance hemodialysis during the first wave of the epidemic in March and April 2020 and were still alive 6 months later. We also investigated associations between the patients diagnosed as infected during the first wave and several clinical, biological, and radiological parameters of COVID-19. Finally, we compared these circulating levels of SARS-CoV-2 antibodies with those of a control group of healthcare workers infected during the same period. Of the 299 hemodialysis patients who recovered from the first wave of the epidemic 6 months before, 59 had a positive SARS-CoV-2 antibody whereas only 45 patients were diagnosed as infected during the first wave of the epidemic. All infected hemodialysis patients developed circulating antibodies. Using a clustering method, a significant correlation was identified between the cluster with the lowest circulating levels of SARS-CoV-2 antibodies and the severity of COVID-19 based on several parameters including CRP, BNP, lymphocyte count, neutrophil-lymphocyte ratio, and oxygen requirements, as well as pulmonary involvement on chest scan. Moreover, the circulating levels of the SARS-CoV-2 antibodies in surviving hemodialysis patients ( The main finding of this study is that all of the surviving hemodialysis patients who were diagnosed with SARS-CoV-2 infection from March to April 2020 developed a persistent humoral response with significant circulating levels of SARS-CoV-2 antibodies, 6 months later. Another important finding is that surviving hemodialysis patients who had more severe disease had lower circulating levels of SARS-CoV-2 antibodies. Finally, circulating levels of SARS-CoV-2 antibodies were similar in surviving hemodialysis patients and healthcare workers without kidney disease.
Sections du résumé
BACKGROUND
BACKGROUND
The humoral response to SARS-CoV-2 infection in hemodialysis patients needs to be clarified.
METHODS
METHODS
In this retrospective study performed in two dialysis facilities, we measured the circulating levels of SARS-CoV-2 antibodies in patients who were on maintenance hemodialysis during the first wave of the epidemic in March and April 2020 and were still alive 6 months later. We also investigated associations between the patients diagnosed as infected during the first wave and several clinical, biological, and radiological parameters of COVID-19. Finally, we compared these circulating levels of SARS-CoV-2 antibodies with those of a control group of healthcare workers infected during the same period.
RESULTS
RESULTS
Of the 299 hemodialysis patients who recovered from the first wave of the epidemic 6 months before, 59 had a positive SARS-CoV-2 antibody whereas only 45 patients were diagnosed as infected during the first wave of the epidemic. All infected hemodialysis patients developed circulating antibodies. Using a clustering method, a significant correlation was identified between the cluster with the lowest circulating levels of SARS-CoV-2 antibodies and the severity of COVID-19 based on several parameters including CRP, BNP, lymphocyte count, neutrophil-lymphocyte ratio, and oxygen requirements, as well as pulmonary involvement on chest scan. Moreover, the circulating levels of the SARS-CoV-2 antibodies in surviving hemodialysis patients (
CONCLUSION
CONCLUSIONS
The main finding of this study is that all of the surviving hemodialysis patients who were diagnosed with SARS-CoV-2 infection from March to April 2020 developed a persistent humoral response with significant circulating levels of SARS-CoV-2 antibodies, 6 months later. Another important finding is that surviving hemodialysis patients who had more severe disease had lower circulating levels of SARS-CoV-2 antibodies. Finally, circulating levels of SARS-CoV-2 antibodies were similar in surviving hemodialysis patients and healthcare workers without kidney disease.
Identifiants
pubmed: 34868683
doi: 10.1155/2021/4747221
pmc: PMC8633850
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4747221Informations de copyright
Copyright © 2021 Henri Boulanger et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Biom J. 2021 Feb;63(2):372-393
pubmed: 32627864
J Am Soc Nephrol. 2020 Sep;31(9):1969-1975
pubmed: 32732391
Kidney Int. 2020 Oct;98(4):1053-1054
pubmed: 32750459
Kidney Int. 2020 Dec;98(6):1519-1529
pubmed: 32858081
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Nephrol Dial Transplant. 2021 Jan 1;36(1):87-94
pubmed: 33340043
Nephrol Dial Transplant. 2021 May 27;36(6):1132-1134
pubmed: 33609131
Diagn Interv Imaging. 2020 Jul - Aug;101(7-8):431-437
pubmed: 32571748
Am J Kidney Dis. 2020 Sep;76(3):440-441
pubmed: 32512038
J Am Soc Nephrol. 2021 May 3;32(5):1033-1036
pubmed: 33637518
Nephron. 2021;145(4):363-370
pubmed: 33902031
Am J Kidney Dis. 2020 Oct;76(4):598
pubmed: 32603711
Am J Kidney Dis. 2021 May;77(5):748-756.e1
pubmed: 33465417
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Kidney Int. 2021 Apr;99(4):791-793
pubmed: 33582109
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
Am J Kidney Dis. 2020 Oct;76(4):490-499.e1
pubmed: 32628990